Doctors find heart risk dips after a year on obesity drug Wegovy
While Novo Nordisk’s Wegovy is being clinically tested for cardiovascular benefits, a real-world trial shows early promise.
By Naomi Kresge, bloomberg
Patients who took the obesity drug Wegovy for a year had a reduced risk of heart disease in an early hint that Novo Nordisk A/S’s best-selling obesity medicine may also have a positive impact on cardiovascular health.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Obesity alone didn’t pose biggest heart risk in London study
For subscribers
Obesity drugs aren't the easy solution to "globesity": WHO
For subscribers
